An evaluation of the emerging vaccines against influenza in children

[1]  Tom Jefferson,et al.  Vaccines for preventing influenza in healthy adults. , 2014, The Cochrane database of systematic reviews.

[2]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy children. , 2012, The Cochrane database of systematic reviews.

[3]  A. Omar,et al.  Cytotoxicity and immunological responses following oral vaccination of nanoencapsulated avian influenza virus H5 DNA vaccine with green synthesis silver nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Jamie Perin,et al.  Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000 , 2012, The Lancet.

[5]  I. Rudan,et al.  Setting priorities for development of emerging interventions against childhood pneumonia, meningitis and influenza , 2012, Journal of global health.

[6]  T. Vesikari,et al.  Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age , 2012, The Pediatric infectious disease journal.

[7]  Vidyashankara G. Iyer,et al.  Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen , 2012, Human vaccines & immunotherapeutics.

[8]  J. Paul.  BMC public health. , 2012, World health & population.

[9]  Harish Nair,et al.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis , 2011, The Lancet.

[10]  Anil Kumar Singh,et al.  Yeast expressed recombinant Hemagglutinin protein of Novel H1N1 elicits neutralising antibodies in rabbits and mice , 2011, Virology Journal.

[11]  J. Treanor,et al.  Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. , 2011, Vaccine.

[12]  G. Glenn,et al.  H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans , 2011, Journal of Virology.

[13]  G. Glenn,et al.  Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico , 2011, Vaccine.

[14]  J. Hedlund,et al.  Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia , 2011, Scandinavian journal of infectious diseases.

[15]  M. Cox,et al.  A fast track influenza virus vaccine produced in insect cells. , 2011, Journal of invertebrate pathology.

[16]  Langzhou Song,et al.  Immunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in Mice , 2011, PloS one.

[17]  E. Hohmann,et al.  Attenuated Listeria monocytogenes vaccine vectors expressing Influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers , 2011, Microbiology and immunology.

[18]  I. Rudan,et al.  An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children , 2011, BMC public health.

[19]  I. Rudan,et al.  An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children , 2011, BMC public health.

[20]  Harish Nair,et al.  An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children , 2011, BMC public health.

[21]  Harish Nair,et al.  An evaluation of emerging vaccines for childhood meningococcal disease , 2011, BMC public health.

[22]  I. Rudan,et al.  An evaluation of oxygen systems for treatment of childhood pneumonia , 2011, BMC public health.

[23]  S. Madhi,et al.  An evaluation of emerging vaccines for childhood pneumococcal pneumonia , 2011, BMC public health.

[24]  M. Cox,et al.  Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. , 2011, Vaccine.

[25]  M. Prausnitz,et al.  Microneedle Vaccination with Stabilized Recombinant Influenza Virus Hemagglutinin Induces Improved Protective Immunity , 2011, Clinical and Vaccine Immunology.

[26]  I. Rudan,et al.  Setting Research Priorities to Reduce Global Mortality from Childhood Pneumonia by 2015 , 2009, PLoS medicine.

[27]  F. Kostolanský,et al.  Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. , 2011, Acta virologica.

[28]  A. Walmsley,et al.  Plant-made vaccines in support of the Millennium Development Goals , 2011, Plant Cell Reports.

[29]  Z. Xiang,et al.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  A. García-Sastre,et al.  NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. , 2010, Vaccine.

[31]  T. Vesikari,et al.  Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Jonathan Liu,et al.  Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process , 2010, Biotechnology and bioengineering.

[33]  S. Faust,et al.  Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study , 2010, BMJ : British Medical Journal.

[34]  Mustafizur Rahman,et al.  Influenza is a Major Contributor to Childhood Pneumonia in a Tropical Developing Country , 2010, The Pediatric infectious disease journal.

[35]  G. Leroux-Roels,et al.  Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. , 2010, Vaccine.

[36]  L. Swartz,et al.  Research priorities for health of people with disabilities: an expert opinion exercise , 2009, The Lancet.

[37]  A. Osterhaus,et al.  MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization , 2009, PloS one.

[38]  J. Hedrick,et al.  Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. , 2009, Vaccine.

[39]  R. Schwartz,et al.  Use of MDCK cells for production of live attenuated influenza vaccine. , 2009, Vaccine.

[40]  T. Kuiken,et al.  Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. , 2009, Vaccine.

[41]  R. Bugarini,et al.  Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. , 2009, The Journal of infectious diseases.

[42]  X. de Radiguès,et al.  Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. , 2009, Vaccine.

[43]  V. Patel,et al.  Setting priorities for global mental health research. , 2009, Bulletin of the World Health Organization.

[44]  J. Oxford,et al.  DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. , 2009, Vaccine.

[45]  D. Tang,et al.  Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines , 2009, Expert review of vaccines.

[46]  G. Rimmelzwaan,et al.  Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara , 2009, Expert review of vaccines.

[47]  I. Rudan.  The complex challenge of setting priorities in health research investments. , 2009, The Indian journal of medical research.

[48]  I. Rudan,et al.  Setting Research Priorities To Reduce Global Mortality from Childhood Diarrhoea by 2015 , 2009, PLoS medicine.

[49]  Stephanie L. Dickinson,et al.  Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. , 2009, Vaccine.

[50]  W. A. Brooks.  A four-stage strategy to reduce childhood pneumonia-related mortality by 2015 and beyond. , 2009, Vaccine.

[51]  I. Rudan,et al.  Research Priorities to Reduce Global Mortality From Newborn Infections by 2015 , 2009, The Pediatric infectious disease journal.

[52]  A. Hyder,et al.  Setting priorities in global child health research investments: guidelines for implementation of CHNRI method. , 2008, Croatian medical journal.

[53]  I. Rudan,et al.  Setting priorities in global child health research investments: universal challenges and conceptual framework. , 2008, Croatian medical journal.

[54]  K. Musiychuk,et al.  Plant-expressed HA as a seasonal influenza vaccine candidate. , 2008, Vaccine.

[55]  N. Mytle,et al.  Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. , 2008, Vaccine.

[56]  Igor Rudan,et al.  Epidemiology and etiology of childhood pneumonia. , 2008, Bulletin of the World Health Organization.

[57]  R. Webster,et al.  Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted; Prepandrix™): a guide to its use as an active immunization against influenza A subtype H5N1 virus , 2008 .

[58]  I. Rudan,et al.  Childhood pneumonia and diarrhoea: setting our priorities right. , 2011, The Lancet. Infectious diseases.

[59]  M. Katze,et al.  Functional Genomic and Serological Analysis of the Protective Immune Response Resulting from Vaccination of Macaques with an NS1-Truncated Influenza Virus , 2007, Journal of Virology.

[60]  E. Waldman,et al.  Effectiveness of influenza vaccination and its impact on health inequalities. , 2007, International journal of epidemiology.

[61]  Adolfo García-Sastre,et al.  Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. , 2007, Vaccine.

[62]  A. Cupo,et al.  A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). , 2007, Viral immunology.

[63]  A. Hyder,et al.  Setting priorities in global child health research investments: assessment of principles and practice. , 2007, Croatian medical journal.

[64]  I. Rudan,et al.  Setting Priorities in Child Health Research Investments for South Africa , 2007, PLoS medicine.

[65]  N. Harvey,et al.  Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines , 2007, Clinical and Vaccine Immunology.

[66]  A. Hyder,et al.  Setting priorities in global child health research investments: assessment of principles and practice. , 2007, Croatian medical journal.

[67]  Keiji Fukuda,et al.  A global pandemic influenza vaccine action plan. , 2006, Vaccine.

[68]  C. Bridges,et al.  The underrecognized burden of influenza in young children. , 2006, The New England journal of medicine.

[69]  Giovanni Apolone,et al.  Influenza vaccine in healthy children: a meta-analysis. , 2005, Vaccine.

[70]  Shabir A Madhi,et al.  A role for Streptococcus pneumoniae in virus-associated pneumonia , 2004, Nature Medicine.

[71]  R. Belshe,et al.  Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination , 2004, The Pediatric infectious disease journal.

[72]  韩旭东,et al.  Viral pneumonia , 2004 .

[73]  R. Gasparini,et al.  Socioeconomic impact of influenza on healthy children and their families , 2003, The Pediatric infectious disease journal.

[74]  K. Edwards,et al.  Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. , 2002, The Journal of infectious diseases.

[75]  R. Mahoney,et al.  The introduction of new vaccines into developing countries. , 1999, Vaccine.

[76]  S. Osajima.  [VIRAL PNEUMONIA]. , 1963, Naika. Internal medicine.